Condition: Cutaneous Squamous Cell Carcinoma (CSCC) · Sponsor: Regeneron Pharmaceuticals
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works compared to surgery
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| Medical Dermatology Specialists - Phoenix | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic - Arizona | Scottsdale, Arizona, United States | Recruiting |
| University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| Arkansas Research Trials | North Little Rock, Arkansas, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Profound Research, Dermatology Medical Group - Oceanside | Oceanside, California, United States | Recruiting |
| Stanford University | Redwood City, California, United States | Recruiting |
| Peak Dermatology, Aesthetics and Wellness | Visalia, California, United States | Recruiting |
| George Washington University Medical Faculty Associates | Washington D.C., District of Columbia, United States | Recruiting |
| Life Clinical Trials | Coral Springs, Florida, United States | Recruiting |
| Dermatology Associates of the Palm Beaches, Integri Research at Dermatology Associates | Delray Beach, Florida, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06585410